Literature DB >> 23400009

CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database.

D-P Dai1, R-A Xu2, L-M Hu3, S-H Wang4, P-W Geng4, J-F Yang5, L-P Yang6, J-C Qian4, Z-S Wang7, G-H Zhu7, X-H Zhang8, R-S Ge9, G-X Hu4, J-P Cai1.   

Abstract

Genetic polymorphisms of CYP2C9 significantly influence the pharmacokinetics and pharmacodynamics of some drugs, which might result in adverse drug effects and therapeutic failure. Several studies have been performed on CYP2C9 genetic polymorphisms in Han Chinese populations. However, these studies only focused on two commonly investigated alleles, *2 and *3, in relatively small sample sizes. To scale up the gene-scanning region and determine relatively precise data on the genetic distribution pattern in Chinese populations, unrelated healthy Han Chinese volunteers from Zhejiang Province (n=1127) and Hebei (n=1000) Province were recruited as subjects for the direct sequencing of all exons of CYP2C9. As a result, 14 previously reported alleles were detected in this work, and 8 of these alleles (*14, *16, *19, *23, *27, *29, *33 and *34) were described for the first time in Chinese populations. In addition, 37 novel mutations were also detected, of which 22 variants were non-synonymous, and 21 new alleles, *36-*56, were designated by the Human CYP Allele Nomenclature Committee. In vitro functional analysis of these 22 novel CYP2C9 variants revealed that 17 mutations had a significant influence on the protein's catalytic activity. Our study provides the most accurate data on CYP2C9 polymorphisms in Han Chinese populations and detects the largest number of novel allelic variants existing to date. These new alleles will greatly enrich the current knowledge of naturally occurring CYP2C9 variants in Chinese populations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23400009     DOI: 10.1038/tpj.2013.2

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  25 in total

1.  In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population.

Authors:  Da-peng Dai; Yu-han Wang; Shuang-hu Wang; Pei-wu Geng; Li-ming Hu; Guo-xin Hu; Jian-ping Cai
Journal:  Acta Pharmacol Sin       Date:  2013-09-30       Impact factor: 6.150

2.  The role of CYP2C9 genetic polymorphism in carvedilol O-desmethylation in vitro.

Authors:  Pei-Pei Pan; Qing-Hua Weng; Chen-Jian Zhou; Yan-Li Wei; Li Wang; Da-Peng Dai; Jian-Ping Cai; Guo-Xin Hu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-12-05       Impact factor: 2.441

3.  Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in CYP2C9 and CYP2C19.

Authors:  Sandhya Devarajan; Irene Moon; Ming-Fen Ho; Nicholas B Larson; Drew R Neavin; Ann M Moyer; John L Black; Suzette J Bielinski; Steven E Scherer; Liewei Wang; Richard M Weinshilboum; Joel M Reid
Journal:  Drug Metab Dispos       Date:  2019-02-11       Impact factor: 3.922

4.  Polymorphic analysis of CYP2C9 gene in Vietnamese population.

Authors:  Nhung Phuong Vu; Thuong Thi Huyen Ma; Ngoc Thi Bich Tran; Hue Thi Thu Huynh; Ton Dang Nguyen; Duong Thuy Nguyen; Hai Van Nong; Ming Ta Michael Lee; Ha Hai Nguyen
Journal:  Mol Biol Rep       Date:  2018-07-05       Impact factor: 2.316

5.  Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX.

Authors:  Alison E Fohner; Renee Robinson; Joseph Yracheta; Denise A Dillard; Brian Schilling; Burhan Khan; Scarlett Hopkins; Bert Boyer; Jynene Black; Howard Wiener; Hemant K Tiwari; Adam Gordon; Deborah Nickerson; Jesse M Tsai; Federico M Farin; Timothy A Thornton; Allan E Rettie; Kenneth E Thummel
Journal:  Pharmacogenet Genomics       Date:  2015-07       Impact factor: 2.089

6.  Genes affecting warfarin response-interactive or additive?

Authors:  Larisa H Cavallari; Julio D Duarte
Journal:  J Clin Pharmacol       Date:  2014-12-30       Impact factor: 3.126

7.  Cytochrome P450 2C9 (CYP2C9) polymorphisms in Chinese Li population.

Authors:  Yipeng Ding; Danlei Yang; Long Zhou; Ping He; Jinjian Yao; Pingdong Xie; Daobo Lin; Dingwei Sun; Pei Sun; Quanni Li; Tingting Geng; Tianbo Jin
Journal:  Int J Clin Exp Med       Date:  2015-11-15

Review 8.  Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes.

Authors:  Tingyu Wang; Yitian Zhou; Guosheng Cao
Journal:  Eur J Clin Pharmacol       Date:  2021-01-29       Impact factor: 2.953

9.  Sampling times and genotyping concerns in bioequivalence evaluation of branded and generic formulations.

Authors:  Xiao-Ying Zhao; Hui-Min Xu; Quan Zhou
Journal:  Ther Clin Risk Manag       Date:  2013-11-25       Impact factor: 2.423

10.  Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism.

Authors:  Young-Hoon Kim; Pureum Kang; Chang-Keun Cho; Eui Hyun Jung; Hye-Jeong Park; Yun Jeong Lee; Jung-Woo Bae; Choon-Gon Jang; Seok-Yong Lee
Journal:  Arch Pharm Res       Date:  2021-07-25       Impact factor: 4.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.